Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors
<p>Glioblastoma is the most common and aggressive malignant brain tumor among all primary brain and central nervous system (CNS) tumors. The median survival time for glioblastoma patients given the current standard of care treatment (surgery, radiation, and chemotherapy) is less than 15 months...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2016
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10161/13365 |